SCHEMBL6417852

SCHEMBL6417852

CSc1nc(-c2ccccc2)cc2nccn12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNK2 Q07912 2/20 0.46
MAP4K2 Q12851 3/20 0.44
MAP4K4 O95819 2/20 0.44
KDR P35968 2/20 0.44
AURKB Q96GD4 2/20 0.44
CHEK1 O14757 1/20 0.44
CSF1R P07333 1/20 0.44
PRKACA P17612 1/20 0.44
CDK8 P49336 1/20 0.44
MAP2K1 Q02750 1/20 0.44
ACVR1 Q04771 1/20 0.44
ROCK1 Q13464 1/20 0.44
DYRK1A Q13627 1/20 0.44
DYRK1B Q9Y463 1/20 0.44
NPC1 O15118 3/20 0.41
LMNA P02545 3/20 0.41
RAB9A P51151 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
MAPT P10636 2/20 0.41
CSNK1E P49674 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3142075 0.78 NPC1 (0.49) TNK2KDRMAP2K1NPC1LMNA
SCHEMBL2573277 0.78 AHR (0.46) TNK2KDRNPC1LMNARAB9A
SCHEMBL6420521 0.76 TDP1 (0.47) TNK2MAP4K2MAP4K4KDRAURKB
SCHEMBL10830686 0.76 TNK2 (0.34) TNK2CDK8ROCK1ALDH1A1ADORA2A
SCHEMBL6506355 0.75 PTPN5 (0.43) MAP4K2MAP4K4KDRAURKBCSF1R
SCHEMBL3607789 0.74 CYP1A2 (0.36) TNK2CSNK1EALDH1A1ADORA2AKMT2A
SCHEMBL5315910 0.74 MAP4K2 (0.42) TNK2MAP4K2MAP4K4KDRAURKB
Hydrochloric Acid SCHEMBL2573564 0.73 CYP1A2 (0.35) TNK2ALDH1A1KMT2A
SCHEMBL6495619 0.73 SYK (0.54) TNK2MAP4K2MAP4K4KDRAURKB
SCHEMBL6415711 0.73 CSNK1E (0.43) TNK2MAP4K2MAP4K4KDRAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050288502-A1 Substituted heterocyclic compounds and methods of use AMGEN, INC. 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288502-A1 Substituted heterocyclic compounds and methods of use MYLK2, IAPP, MAPT TNK2 1983/4885MAP4K2 854/4885MAP4K4 679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.